首页> 外文期刊>Journal of the Neurological Sciences: Official Bulletin of the World Federation of Neurology >Cytotoxic T cell activity against the peptide, AYRARALEL, from Yo protein of patients with the HLA A24 or B27 supertype and paraneoplastic cerebellar degeneration.
【24h】

Cytotoxic T cell activity against the peptide, AYRARALEL, from Yo protein of patients with the HLA A24 or B27 supertype and paraneoplastic cerebellar degeneration.

机译:HLA A24或B27超型和副肿瘤性小脑变性患者的Yo蛋白对肽AYRARALEL的细胞毒性T细胞活性。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

OBJECTIVE: To determine a peptide that reacts with cytotoxic T cells (CTL) of patients with paraneoplastic cerebellar degeneration and anti-Yo antibodies with either HLA A24 or B27 supertype. METHOD: We studied CTL activity of four patients, three were HLA A24-positive and one did not have HLA A24 but had B27 supertype. After an incubation of mononuclear cells with or without peptide and IL-2, CD8-rich fraction was prepared by treatment with Magnetic Cell Sorting system (MACS) twice. CTL activity was calculated by 51Cr release from transfectant, C1RA*2402 as target cells. The peptide-binding assay was examined by flow cytometry. RESULTS: Two of three HLA A 24-positive patients demonstrated CTL activity against the Yo peptide, AYRARALEL. CTL activity was found to be 19.5% and 11.7% at the effector/target (E/T) ratio of 23:1 and 11:1, respectively. A patient who did not have HLA A24 but had A2 and B27 supertype possessed a CTL activity of 19.4% with 15:1 as E/T ratio. The peptide could bind to HLA A*2402 molecules but not to A*0201. CONCLUSIONS: We showed CTL activity in two of three Japanese patients with HLA A24 by using HLA A*2402 transfectant cells as the target. In addition, we identified the first Japanese patient who had B27 supertype, and suggested that the same peptide, AYRARALEL, could be recognized by CTL in this patient.
机译:目的:确定与副肿瘤小脑变性和HLA A24或B27超型抗Yo抗体的患者的细胞毒性T细胞(CTL)反应的肽。方法:我们研究了4例患者的CTL活性,其中3例是HLA A24阳性,而1例没有HLA A24但具有B27超型。温育有或没有肽和IL-2的单核细胞后,通过用磁性细胞分选系统(MACS)处理两次来制备富含CD8的级分。通过从作为靶细胞的转染子C1RA * 2402中释放51Cr来计算CTL活性。通过流式细胞术检查肽结合测定。结果:三名HLA A 24阳性患者中有两名表现出针对Yo肽AYRARALEL的CTL活性。发现在效应子/靶标(E / T)比率为23:1和11:1时,CTL活性分别为19.5%和11.7%。没有HLA A24但具有A2和B27超型的患者的CTL活性为19.4%,E / T比为15:1。该肽可以与HLA A * 2402分子结合,但不能与A * 0201结合。结论:我们通过使用HLA A * 2402转染细胞作为靶标,在三名日本HLA A24患者中的两名显示了CTL活性。此外,我们确定了第一位具有B27超型的日本患者,并建议在该患者中CTL可以识别相同的肽AYRARALEL。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号